Drug Profile


Alternative Names: DNCB

Latest Information Update: 31 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Antivirals; Nitrobenzenes
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alopecia; Atopic dermatitis; HIV infections; Malignant melanoma; Systemic lupus erythematosus

Most Recent Events

  • 12 Apr 2000 A study in patients with atopic dermatitis has been added to the Skin disorders therapeutic trials section
  • 03 Apr 2000 Investigation in Atopic dermatitis in Japan (Topical)
  • 30 Jul 1998 A controlled, quality of life analysis has been added to the Viral infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top